TriPath "Direct To Vial" AutoCyte Prep Use Must Be Reviewed By FDA
This article was originally published in The Gray Sheet
Executive Summary
FDA will need to approve data comparing "direct to vial" use of TriPath Imaging's AutoCyte PREP system to historical performance using traditional Pap smear before the company can use the information to market the system, according to a recent agency warning letter.